Borneol

Summary

Borneol (CHEMBL1097205) is an approved small-molecule volatile oil component targeting TRPV3; indicated across 2 conditions including allergic rhinitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (TRPV3)
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 154.25 Da · C10H18O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1097205
Name	Borneol
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	64685
ChEBI	CHEBI:28093
Molecular formula	C10H18O
Molecular weight	154.25
InChIKey	DTGKSKDOIYIVQL-UHFFFAOYSA-N

SMILES: CC1(C2CCC1(C(C2)O)C)C

IUPAC name: 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol

ChEBI definition: A bornane monoterpenoid that is 1,7,7-trimethylbicyclo[2.2.1]heptane substituted by a hydroxy group at position 2.

Pharmacological roles (ChEBI): volatile oil component.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: (+/-)-borneol, (+/-)-isoborneol, Bingpian, Borneol, dl-, Borneolum syntheticum, Camphol, Endo-borneol, FEMA NO. 2157, Hechenglongnao, NSC-60223, borneol

Patent coverage: 39,121 distinct patent families (63,905 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TRPV3	TRPV3	Activation	2.46	0%	Q8NET8

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPV3.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPV3

Dominant GO biological processes

GO term	Targets
actin filament organization	1
osmosensory signaling pathway	1
response to temperature stimulus	1
negative regulation of hair cycle	1
calcium ion transmembrane transport	1
positive regulation of calcium ion import	1
calcium ion import across plasma membrane	1
monoatomic ion transport	1
calcium ion transport	1
monoatomic ion transmembrane transport	1
sodium ion transmembrane transport	1
transmembrane transport	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic rhinitis	2	MONDO:0011786	EFO:0005854

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01659580	PHASE3	COMPLETED	Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
NCT05901532	PHASE2	COMPLETED	Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
NCT02029118	EARLY_PHASE1	COMPLETED	Acupoint Application in Patients With Stable Angina Pectoris (AASAP)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
CANNABINOL	ChEMBL	Phase 3	TRPV3
CANNABIDIVARIN	ChEMBL	Phase 2	TRPV3
CANNABIGEROL	ChEMBL	Phase 2	TRPV3
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV3
camphor (synthetic)	PubChem	Approved	TRPV3